AstraZeneca plc (AZN) Earns Buy Rating from Deutsche Bank AG
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Deutsche Bank AG in a report released on Wednesday.
A number of other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of AstraZeneca plc in a research report on Wednesday, November 2nd. Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a research report on Monday, November 7th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.62) price objective on AstraZeneca plc and gave the company a “sell” rating in a research report on Tuesday, October 4th. Bryan, Garnier & Co reaffirmed a “buy” rating and set a GBX 5,100 ($63.27) price objective on shares of AstraZeneca plc in a research report on Tuesday, November 22nd. Finally, Morgan Stanley raised their price objective on AstraZeneca plc from GBX 5,000 ($62.03) to GBX 5,800 ($71.95) and gave the company an “overweight” rating in a research report on Friday, August 19th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and an average target price of GBX 4,958.40 ($61.51).
Shares of AstraZeneca plc (LON:AZN) opened at 4238.50 on Wednesday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The company’s market capitalization is GBX 53.62 billion. The firm’s 50-day moving average is GBX 4,592.74 and its 200 day moving average is GBX 4,592.37.
WARNING: “AstraZeneca plc (AZN) Earns Buy Rating from Deutsche Bank AG” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2016/11/30/astrazeneca-plc-azn-earns-buy-rating-from-deutsche-bank-ag-2.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.